Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial

Reuters

昨天

Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial

Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation (DIFS™) device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America (RSNA), indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542003-en) on October 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573232499"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573232499\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573232499?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573232499","market":"fut","top_or_hot":-1,"title":"Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation (DIFS™) device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America (RSNA), indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542003-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation (DIFS™) device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America (RSNA), indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542003-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL23K0PV:1","article_id":"2573232499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573232499","pubTimestamp":1759926624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation  device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America , indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination  and Montreal Cognitive Assessment  scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4082":"医疗保健设备","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","NXL":"Nexalin Technology, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Nexalin Technology Gen2 SYNC设备在阿尔茨海默病临床试验中显示出显著的认知改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NXL":0.9},"content_text":"Nexalin Technology Gen2 SYNC Device Shows Significant Cognitive Improvement in Alzheimers Clinical Trial\n    \n\n        Nexalin Technology Inc. has announced the publication of additional positive clinical data for its Gen-2 SYNC 40-Hz Deep Intracranial Frequency Stimulation (DIFS™) device in the treatment of mild Alzheimer's disease. The results, already published in Radiology, the flagship journal of the Radiological Society of North America (RSNA), indicate that the device significantly improves cognitive performance and enhances brain network connectivity. The randomized, sham-controlled trial found clinically meaningful gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores compared to baseline and to the sham group. Resting-state functional MRI demonstrated enhanced connectivity between the hippocampus and key cortical regions. No adverse events were reported during the treatment period.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542003-en) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}